Zeinab Dalloul | Cancer Genomics Computational Studies | Research Excellence Award

Published on by Computational Biologists

Research Excellence Award

Zeinab Dalloul
Algentics

Zeinab Dalloul
Affiliation Algentics
Country Canada
Scopus ID 57191171462
Documents 14
Citations 110
h-index 5
Subject Area Cancer Genomics Computational Studies
Event Computational Biologists Awards

Zeinab Dalloul is affiliated with Algentics in Canada and is represented in the supplied scholarly records within the field of cancer genomics computational studies. The supplied Scopus record reports 14 documents, 110 citations, and an h-index of 5. These indicators provide quantitative information about the indexed scholarly record and can be considered alongside publication content, subject relevance, and other evidence in an academic recognition review. [1]

Abstract

Zeinab Dalloul is affiliated with Algentics in Canada and is represented in the supplied scholarly records as a researcher working within cancer genomics computational studies. Her indexed profile reports 14 documents, 110 citations, and an h-index of 5. These bibliometric indicators provide measurable information about publication activity and citation reach within indexed literature. Her research area connects computational approaches with cancer genomics, a field that integrates biological data, computational analysis, and genomic interpretation to investigate cancer-related molecular characteristics. The Research Excellence Award profile considers her documented research record, subject alignment, scholarly output, and measurable citation indicators in relation to computational biology. [1]

Keywords

Cancer Genomics, Computational Biology, Genomic Analysis, Bioinformatics, Cancer Research, Computational Genomics, Biomedical Data Analysis, Research Excellence. [1]

Introduction

Computational cancer genomics applies computational and bioinformatic methods to genomic and molecular datasets generated through cancer research. Such approaches support the analysis of complex biological information and the interpretation of genomic variation, molecular patterns, and disease-associated datasets. Dalloul’s supplied researcher profile is situated within this interdisciplinary subject area and is documented through an indexed Scopus author record. [1]

Research Profile

Dalloul’s research profile is associated with cancer genomics computational studies, placing the supplied record at the intersection of genomics, computational biology, and biomedical research. The supplied bibliometric record identifies 14 indexed documents and 110 citations, with an h-index of 5. These measures describe publication and citation activity but do not independently establish the scientific content, methodology, or significance of individual studies. [1]

Research Contributions

Within cancer genomics computational studies, research contributions may involve the organization, analysis, and interpretation of genomic datasets using computational methods. Dalloul’s documented subject area indicates relevance to this research domain, while the available publication and citation indicators provide evidence of an indexed scholarly record. Specific methodological contributions should be assessed from individual publications and their full scientific content. [1]

Publications

The supplied Scopus information records 14 documents associated with Zeinab Dalloul’s author profile. This document count represents indexed scholarly output within the referenced database and should be interpreted according to database coverage and author-profile attribution. Individual publication titles, journals, publication dates, authorship positions, and article-level identifiers were not supplied and therefore are not reproduced here. [1]

Research Impact

The supplied bibliometric record reports 110 citations and an h-index of 5. Citation counts provide one quantitative measure of how frequently indexed publications have been cited, while the h-index combines publication and citation information into a single indicator. Such metrics can vary according to database coverage, field characteristics, publication age, and author disambiguation, so they are most appropriately considered alongside qualitative evidence. [1]

Award Suitability

The supplied profile contains an identified affiliation with Algentics, a defined subject area in cancer genomics computational studies, an indexed publication record, and measurable citation indicators. These elements provide documented information that can be considered within a research-recognition review associated with the Computational Biologists Awards. Final recognition remains subject to the award program’s applicable eligibility, evaluation, and verification procedures. [3]

Conclusion

Zeinab Dalloul’s supplied academic profile describes a researcher affiliated with Algentics in Canada and associated with cancer genomics computational studies. The available Scopus information records 14 documents, 110 citations, and an h-index of 5. These data provide a concise bibliometric description of the indexed research record, while detailed assessment of scientific contributions requires examination of the underlying publications and supporting scholarly evidence. [1] [2]

References

  1. Elsevier. (n.d.). Scopus author details: Zeinab Dalloul, Author ID 57191171462. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57191171462
  2. Review article. (2025.) Leveraging liquid biopsy to uncover resistance mechanisms and guide personalized immunotherapy.
    https://doi.org/10.1016/j.tranon.2025.102445
  3. Computational Biologists Awards. (2026. )  Computational Biologists Awards.
    https://computationalbiologists.com/

Jin-Ji Yang | Pulmonary oncology | Personalized Medicine Innovation

Published on by Computational Biologists

Personalized Medicine Innovation

Jin-Ji Yang
Guangdong Provincial People’s Hospital

Jin-Ji Yang
Affiliation Guangdong Provincial People’s Hospital
Country China
Scopus ID 57543111300
Documents 1
Citations 2
h-index 1
Subject Area Pulmonary oncology
Event Computational Biologists Awards
ORCID 0000-0002-8498-0119

Jin-Ji Yang is affiliated with Guangdong Provincial People’s Hospital in China and is identified in Scopus under Author ID 57543111300. The documented research subject area is pulmonary oncology, providing a clinical and biomedical context for considering personalized medicine and computational approaches. The available bibliometric record currently lists one document, two citations, and an h-index of one. [1] The researcher’s ORCID identifier provides an additional persistent scholarly identity record. [2]

Abstract

Jin-Ji Yang is a researcher affiliated with Guangdong Provincial People’s Hospital whose documented subject area is pulmonary oncology. The available Scopus record identifies one scholarly document, two citations, and an h-index of one. These metrics provide a limited quantitative snapshot of the researcher’s indexed scholarly output and citation activity. [1] The research profile is additionally associated with ORCID identifier 0000-0002-8498-0119, supporting persistent identification across scholarly systems. [2] Within personalized medicine, pulmonary oncology represents a field where clinical information, molecular evidence, and computational analysis can contribute to individualized research frameworks. This article summarizes the documented profile and its relevance to the Computational Biologists Awards.

Keywords

Personalized Medicine; Pulmonary Oncology; Computational Biology; Biomedical Research; Clinical Informatics; Oncology; Precision Medicine; Guangdong Provincial People’s Hospital; Research Impact; Computational Biologists Awards.

Introduction

Personalized medicine integrates patient-specific biological and clinical information to support more individualized approaches to research and healthcare. Computational biology contributes analytical methods for interpreting complex biomedical datasets. Within pulmonary oncology, these approaches can support investigation of disease characteristics and treatment-related questions. Yang’s documented subject area places the researcher within this interdisciplinary context. [1]

Research Profile

Jin-Ji Yang is affiliated with Guangdong Provincial People’s Hospital in China, with pulmonary oncology identified as the recorded subject area. The Scopus author record currently contains one document and two citations, with an h-index of one. [1] ORCID registration provides a persistent identifier that can help distinguish the researcher within scholarly communication systems. [2]

Research Contributions

The documented research area of pulmonary oncology provides a basis for examining questions at the intersection of oncology, clinical research, and personalized medicine. Computational approaches in such settings may involve structured analysis of biological or clinical information. The available record, however, does not provide sufficient evidence to attribute specific computational methods or broader contributions beyond the indexed subject classification. [1]

Publications

The available Scopus author information records one document for Jin-Ji Yang. [1] Because the supplied bibliographic information does not include the publication title, journal, publication year, or DOI, those details are not inferred here. The indexed document count should therefore be understood as a bibliometric record rather than a complete description of the researcher’s entire scholarly output.

Research Impact

The supplied Scopus metrics report two citations and an h-index of one for the identified author record. [1] These indicators describe indexed citation activity at the time represented by the record and should not be interpreted independently as a comprehensive measure of research influence. Citation counts can vary between databases, disciplines, publication periods, and indexing practices, while ORCID provides identification rather than an impact metric. [2]

Award Suitability

For an award review focused on personalized medicine innovation, the documented affiliation and pulmonary oncology subject area provide relevant professional context. [1] The available record can support consideration of subject-area alignment, while a complete assessment would ordinarily require the specific publication, research methods, documented findings, and evidence of innovation supplied in an application. The Computational Biologists Awards website provides the relevant award context. [3]

Conclusion

Jin-Ji Yang’s documented scholarly profile connects Guangdong Provincial People’s Hospital with pulmonary oncology and a research context relevant to personalized medicine. The current indexed record reports one document, two citations, and an h-index of one. [1] ORCID further establishes a persistent researcher identifier. [2] Additional publications, methodological details, and research outcomes would provide broader evidence for evaluating the scope of computational or personalized-medicine contributions.

References

  1. Elsevier. (n.d.). Scopus author details: Jin-Ji Yang, Author ID 57543111300. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57543111300
  2. ORCID. (n.d.). Jin-Ji Yang — ORCID record. ORCID.
    https://orcid.org/0000-0002-8498-0119
  3. Computational Biologists Awards. (2026.)  Computational Biologists Awards.
    https://computationalbiologists.com/
  4. Research Article (2021. ) Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
    https://doi.org/10.1002/gcc.23005

Weiling He | Cancer Genomics Computational Studies | Best Researcher Award

Published on by Computational Biologists

Prof. Weiling He | Cancer Genomics Computational Studies | Best Researcher Award

Professor at Xiamen University, China

Dr. Weiling He is a leading figure in precision oncology, serving as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor, and President of Xiang’an Hospital at Xiamen University. He is widely recognized for his contributions to cancer treatment, particularly in the domains of tumor microenvironments and drug resistance. Honored with the National Natural Science Foundation of China’s Excellent Young Scientist Fund and recognized as a Distinguished Young Medical Talent of Guangdong Province, Dr. He has established himself as a trailblazer in translational medical research. His prolific output includes over 50 SCI-indexed publications and six granted patents, underscoring his influence in both academia and clinical application.

Profile

Scopus

Education

Dr. He holds both an MD and a PhD, equipping him with a robust foundation for navigating the complex landscape of cancer research and treatment. His academic journey reflects a commitment to scientific excellence and multidisciplinary learning, enabling him to bridge the gap between theoretical research and clinical practice. The integration of medicine and scientific inquiry during his training shaped his ongoing work in precision medicine, translational oncology, and systems biology.

Experience

With a career marked by leadership and innovation, Dr. He currently serves as the President of Xiang’an Hospital at Xiamen University. He has led more than 20 research projects at the national and provincial levels, including prestigious programs under the National Key R&D Initiative and the National Natural Science Foundation of China. Dr. He has also contributed extensively to industry-academia collaboration, participating in strategic projects like the Guangdong Soft Science Program and the Guangzhou Future Industry Initiative. His academic affiliations include leadership roles in over ten national medical associations, reflecting a deep engagement with both clinical and academic ecosystems.

Research Interest

Dr. He’s research focuses on unraveling the mechanisms of tumor drug resistance, exploring metastasis pathways, and analyzing the tumor microenvironment. He is particularly interested in precision interventional therapy and the development of biomaterials and microfluidic technologies for real-time monitoring and treatment. His interdisciplinary approach combines oncology, engineering, and systems biology to improve the outcomes of metastatic cancer therapies. Through collaborative research with institutions such as Sun Yat-sen University and Emory University, he advances new methodologies in clinical translation and integrative cancer treatment.

Award

Dr. Weiling He has received several distinguished honors throughout his career. Among them, the National Natural Science Foundation of China awarded him the Excellent Young Scientist Fund, recognizing his outstanding potential and research impact in oncology. In addition, he was named a Distinguished Young Medical Talent of Guangdong Province, affirming his influence on medical innovation and leadership. His work is frequently acknowledged in national and international forums, and he has played a pivotal role in advancing precision medicine initiatives across China.

Publication

Dr. He has authored more than 50 papers indexed in SCI journals, with several appearing in top-tier publications. Notable recent works include:

“Immune Microenvironment Remodeling in Colorectal Cancer,” Cancer Immunology Research, 2020 – cited 326 times.

“Dual Nanoparticle Delivery in Precision Oncology,” Advanced Science, 2021.

“Microfluidic Chips for Real-time Tumor Monitoring,” Nature Communications, 2022.

“Translational Biomaterials in Interventional Therapy,” Science Translational Medicine, 2023 (cover article).

“Integrated Oncology Systems for Drug Resistance,” Nature Cancer, 2023.

“Microsphere Technology for Metastatic Cancer,” Advanced Science, 2024.

“Tumor Sensitization Targets for Interventional Therapy,” Nature Communications, 2024.

These publications have garnered over 1000 citations in total, with multiple works recognized as “Highly Cited Papers” in their respective fields.

Conclusion

Dr. Weiling He’s exceptional academic record, impactful research, numerous high-impact publications, robust patent portfolio, and her pivotal role in the advancement of precision oncology mark her as a standout candidate for the Best Researcher Award. Her commitment to interdisciplinary innovation and translational impact makes her not only deserving of this honor but a role model for future generations in computational and medical biology.

Ivo Gut | Cancer Genomics Computational Studies | Outstanding Scientist Award

Published on by Computational Biologists

Dr. Ivo Gut | Cancer Genomics Computational Studies |Outstanding Scientist Award

Director at Centro Nacional de Analisis Genomico, Spain.

Dr. Ivo Glynne Gut is an internationally recognized genomics expert, known for pioneering contributions in genome analysis, technology development, and translational research. Born in Basel, Switzerland, in 1960, he holds dual Swiss and British nationality and is fluent in German, English, French, and Spanish. Over a distinguished career spanning more than three decades, he has significantly influenced cancer genomics, rare diseases, epigenetics, and single-cell biology. Dr. Gut is currently the Director General and CEO of the Centro Nacional de Análisis Genómico (CNAG) in Barcelona, a leading genome analysis center in Southern Europe.

🎓Academic Background:

Dr. Ivo Glynne Gut embarked on his academic journey in the field of chemistry at the University of Basel, Switzerland. He earned his undergraduate degree in Chemistry in 1985, laying a strong foundation in the chemical sciences. Demonstrating a keen interest in the physical aspects of chemistry, he pursued and completed a Ph.D. in Physical Chemistry at the same institution in 1990. His doctoral studies equipped him with a profound understanding of the physical principles underlying chemical systems, setting the stage for his future contributions to genomics and molecular biology.

Profile:

💼 Professional Experience:

Dr. Ivo Glynne Gut is a renowned expert in genomics with a career spanning both academia and large-scale research infrastructures. He served as the Director of the Centro Nacional de Análisis Genómico (CNAG) in Spain, where he led high-throughput sequencing efforts for large genomic projects. Prior to that, he was a key scientist at the Centre National de Génotypage (CNG) in France, contributing to major European and international genomics initiatives. Dr. Gut has played a pivotal role in advancing personalized medicine, population genomics, and cancer research through his leadership and innovative approaches in genome analysis. His work bridges cutting-edge technology development with impactful biomedical applications.

🧪 Scientific and Research Excellence:

Dr. Gut’s scientific journey has been defined by a consistent drive to develop and apply innovative technologies to solve complex biomedical problems. His work has led to the creation of gold-standard tools, such as bisulphite pyrosequencing for DNA methylation analysis, and to the foundation of Epigenomics AG, which commercialized the Septin9 blood-based test for colon cancer detection. He played a key role in several landmark genome-wide association studies (GWAS) and was instrumental in uncovering critical genetic mutations in various cancers, including lung cancer, melanoma, and chronic lymphocytic leukemia (CLL). His recent focus on single-cell genomics has opened new frontiers in understanding immune cell dynamics in health and disease.

🌍 International Collaborations and Initiatives:

Dr. Gut’s influence extends globally through his participation in and leadership of major international initiatives. These include the International Cancer Genome Consortium (ICGC), International Human Epigenome Consortium (IHEC), and the 1+Million Genomes Initiative. He has chaired quality control working groups, led genomic infrastructure projects like RD-Connect and EASI-Genomics, and participated in European flagship programs in cancer and rare disease research. His involvement has shaped global best practices in genomic data analysis and policy.

🧠 Areas of Expertise:

His areas of specialization include genomics, bioinformatics, cancer biology, rare diseases, high-throughput sequencing, DNA/protein analysis methods, and the development of omics technologies. His interdisciplinary expertise has allowed him to lead from both technological and clinical fronts.

🏆Honors and Recognition:

Dr. Gut’s excellence has been widely recognized, notably with the “Stars of Europe” Prize awarded to the READNA consortium he coordinated. He also holds several prestigious fellowships and has served on influential scientific advisory boards for institutions including Genome Canada, ELIXIR, and the German Federal Ministry of Education and Research (BMBF). His patented inventions (24 in total) have had significant translational impact, further exemplifying his role as a bridge between discovery and real-world application.

🏥 Leadership and Institutional Impact:

As founding director of CNAG, Dr. Gut has overseen its evolution into a powerhouse of genomic research, managing a team of over 130 professionals and an annual budget of €14 million. Under his leadership, CNAG has achieved ISO certifications, produced over 400 studies annually, and contributed crucial genomic infrastructure and insight to the Spanish healthcare system, particularly in cancer and rare disease diagnostics. His role encompasses scientific strategy, operations, human resources, finance, and stakeholder engagement with ministries of research and health.

Publications:

  1. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, … Gut IG. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nature Genetics. 41(10):1094-1099, 2009. (Cited by 4396)

  2. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, … Gut IG. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nature Genetics. 40(8):955-962, 2008. (Cited by 3314)

  3. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, … Gut IG. The repertoire of mutational signatures in human cancer. Nature. 578(7793):94-101, 2020. (Cited by 3096)

  4. Pan-cancer analysis of whole genomes. Nature. 578(7793):82-93, 2020. (Cited by 2707)

  5. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, … A large-scale, consortium-based genomewide association study of asthma. New England Journal of Medicine. 363(13):1211-1221, 2010. (Cited by 2519)

  6. Rhie A, McCarthy SA, Fedrigo O, Damas J, Formenti G, Koren S, … Gut IG. Towards complete and error-free genome assemblies of all vertebrate species. Nature. 592(7856):737-746, 2021. (Cited by 2443)

  7. International network of cancer genome projects. International Cancer Genome Consortium. Nature. 464(7291):993, 2010. (Cited by 2431)

  8. SEARCH Collaborative Group, Gut IG. SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. New England Journal of Medicine. 359(8):789-799, 2008. (Cited by 2361)

  9. Lappalainen T, Sammeth M, Friedländer MR, ‘t Hoen PAC, Monlong J, … Gut IG. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 501(7468):506-511, 2013. (Cited by 2148)

  10. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, … Gut IG. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 448(7152):470-473, 2007. (Cited by 2023)

  11. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, … Gut IG. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 475(7354):101-105, 2011. (Cited by 1980)

  12. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, … Gut IG. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 452(7187):633-637, 2008. (Cited by 1514)

  13. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, … Gut IG. Genome-wide association study identifies eight loci associated with blood pressure. Nature Genetics. 41(6):666-676, 2009. (Cited by 1465)

  14. Quesada V, Conde L, Villamor N, Ordóñez GR, Jares P, Bassaganyas L, … Gut IG. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics. 44(1):47-52, 2012. (Cited by 1306)

  15. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KCC, Taylor J, … Gut IG. A genome-wide association study of global gene expression. Nature Genetics. 39(10):1202-1207, 2007. (Cited by 1184)

  16. Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, … Gut IG. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 526(7574):519-524, 2015. (Cited by 1094)

  17. Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, … Gut IG. The evolutionary history of 2,658 cancers. Nature. 578(7793):122-128, 2020. (Cited by 1066)

  18. Prado-Martinez J, Sudmant PH, Kidd JM, Li H, Kelley JL, … Gut IG. Great ape genetic diversity and population history. Nature. 499(7459):471-475, 2013. (Cited by 1009)

  19. Heyn H, Li N, Ferreira HJ, Moran S, Pisano DG, Gomez A, Diez J, … Gut IG. Distinct DNA methylomes of newborns and centenarians. Proceedings of the National Academy of Sciences. 109(26):10522-10527, 2012. (Cited by 932)

  20. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nature Protocols. 2(9):2265-2275, 2007. (Cited by 868)